AUR-AG0M-TTP1-A-2-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.220
- UV_RESPONSE_DN+0.220
- PROTEIN_SECRETION+0.210
- G2M_CHECKPOINT+0.200
- E2F_TARGETS+0.180
- PANCREAS_BETA_CELLS+0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.130
- ALLOGRAFT_REJECTION+0.120
- TGF_BETA_SIGNALING+0.100
- SPERMATOGENESIS+0.080
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- ESTROGEN_RESPONSE_EARLY-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- OXIDATIVE_PHOSPHORYLATION-0.360
- XENOBIOTIC_METABOLISM-0.350
- FATTY_ACID_METABOLISM-0.340
- HYPOXIA-0.340
- ESTROGEN_RESPONSE_LATE-0.320
- INTERFERON_ALPHA_RESPONSE-0.290
- P53_PATHWAY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475135 | — | — | 0.844 |
| 2 | SRR2932842 | — | — | 0.815 |
| 3 | SRR12202470 | — | — | 0.803 |
| 4 | AUR-AE5H-TTM1-A-1-1-R-A742-41 | — | E | 0.791 |
| 5 | ERR2598089 | fetal | fetal | 0.790 |
| 6 | 955985ca-7d97-4911-927a-3803e669a805 | — | — | 0.786 |
| 7 | TCGA-AC-A2QH-01A-11R-A18M-07 | — | D | 0.780 |
| 8 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.779 |
| 9 | s0122214 | — | — | 0.777 |
| 10 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |